EU approves AstraZeneca’s drug for adjunct use in Type-1 diabetes

(Reuters) – British drugmaker AstraZeneca Plc said on Monday the European Commission approved its diabetes drug Forxiga for use as an oral supplement to insulin in adults with a rare type of the disease.

Forxiga can now be used along with insulin in patients with Type-1 diabetes and a Body Mass Index (BMI) of 27 or more when insulin alone has not been able to control blood sugar levels, the company said Type-1 diabetes is a chronic condition in which the pancreas produces little or no insulin hormone.

More here –>

Print Friendly, PDF & Email